Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled trial of continuous subcutaneous apomorphine infusion in Parkinson's disease with motor fluctuations
NL-OMON41299Phase 3Active, not recruiting
- Sponsor
- Britannia Pharmaceuticals
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Apomorphine subcutaneous infusion with Placebo subcutaneous infusion (2 arms). Primary endpoint: Absolute change in OFF time. Started May 2014; status: active, not recruiting.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON41299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41299.